Rajat Bhattacharya
Overview
Explore the profile of Rajat Bhattacharya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
873
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ghosh S, Fan F, Powell R, Park Y, Stephan C, Kopetz E, et al.
Ther Adv Med Oncol
. 2024 Dec;
16:17588359241303302.
PMID: 39664300
Background: is frequently mutated in the tumors of patients with metastatic colorectal cancer (mCRC) and thus represents a valid target for therapy. However, the strategies of targeting KRAS directly and...
2.
Chattopadhyay C, Roszik J, Bhattacharya R, Alauddin M, Mahmud I, Yadugiri S, et al.
Br J Cancer
. 2024 Oct;
131(11):1846-1857.
PMID: 39394450
Background: Uveal melanoma (UM) is a highly aggressive disease with very few treatment options. We previously demonstrated that mUM is characterized by high oxidative phosphorylation (OXPHOS). Here we tested the...
3.
Ghosh S, Fan F, Powell R, Park Y, Stephan C, Kopetz E, et al.
bioRxiv
. 2024 Sep;
PMID: 39282351
Background: is frequently mutated in the tumors of patients with metastatic colorectal cancer (mCRC) and thus represents a valid target for therapy. However, the strategies of targeting KRAS directly and...
4.
Chattopadhyay C, Roszik J, Bhattacharya R, Alauddin M, Mahmud I, Yadugiri S, et al.
bioRxiv
. 2024 Jan;
PMID: 38293232
Purpose: Uveal melanoma (UM) is a highly aggressive disease with very few treatment options. We previously demonstrated that mUM is characterized by high oxidative phosphorylation (OXPHOS). Here we tested the...
5.
Ghosh S, Fan F, Powell R, Roszik J, Park Y, Stephan C, et al.
Mol Cancer Ther
. 2023 Jun;
22(8):962-975.
PMID: 37310170
Significance: Our unbiased preclinical studies have identified vincristine as an effective combination partner for the MEK inhibitor trametinib and provide a novel therapeutic option to be studied in patients with...
6.
Fan F, Ghosh S, Powell R, Roszik J, Park Y, Sobieski M, et al.
PLoS One
. 2023 Mar;
18(3):e0281063.
PMID: 36952536
Metastatic colorectal cancer (mCRC) is the second leading cause of cancer deaths in the United States. More than 50% of patients with mCRC harbor mutations of the oncogenic driver RAS...
7.
Chattopadhyay C, Bhattacharya R, Roszik J, Khan F, Wells G, Villanueva H, et al.
Cancers (Basel)
. 2022 Dec;
14(24).
PMID: 36551732
Uveal melanoma originating in the eye and metastasizing to the liver is associated with poor prognosis and has only one approved therapeutic option. We hypothesized that liver-borne growth factors may...
8.
Fan F, Roszik J, Xia L, Ghosh S, Wang R, Ye X, et al.
Cancers (Basel)
. 2022 Apr;
14(8).
PMID: 35454887
Proteins that interact with cytoskeletal elements play important roles in cell division and are potentially important targets for therapy in cancer. Cytospin-A (CYTSA), a protein known to interact with actin...
9.
Rathore M, Zhang W, Wright M, Bhattacharya R, Fan F, Vaziri-Gohar A, et al.
Mol Cancer Res
. 2022 Mar;
20(6):996-1008.
PMID: 35276002
Implications: This body of work highlighted a potential strategy of using HER3 antibodies in combination with standard chemotherapy agents for treating patients with either KRAS wild-type or KRAS mutant metastatic...
10.
Pichler M, Rodriguez-Aguayo C, Nam S, Dragomir M, Bayraktar R, Anfossi S, et al.
Gut
. 2020 Jan;
69(10):1818-1831.
PMID: 31988194
Objective: To investigate the function of a novel primate-specific long non-coding RNA (lncRNA), named FLANC, based on its genomic location (co-localised with a pyknon motif), and to characterise its potential...